ストックスクリーナーアプリを入手
5.0699
0.79%
-0.0099
前日終値:
$5.06
開ける：
$5.06
24時間の取引高:
142
Relative Volume:
0.00
時価総額：
$23.13M
収益：
$20.97M
当期純損益:
$-118.51M
株価収益率:
-2.315
EPS:
-2.19
ネットキャッシュフロー:
$-94.45M
1週間 パフォーマンス:
+2.04%
1か月 パフォーマンス:
-3.46%
6か月 パフォーマンス:
+59.37%
1年 パフォーマンス:
-46.81%
1日の値動き範囲:
$5.06
$5.06
1週間の範囲:
$4.75
$5.203
52週間の値動き範囲:
$2.7084
$11.52
Cara Therapeutics Inc Stock (CARA) Company Profile
名前
Cara Therapeutics Inc
セクター
電話
203-406-3700
住所
400 ATLANTIC STREET, SUITE 500, STAMFORD, CT
CARA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CARA
Cara Therapeutics Inc
|
5.06 | 23.13M | 20.97M | -118.51M | -94.45M | -2.19 |
|
VRTX
Vertex Pharmaceuticals Inc
|
511.27 | 130.68B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
671.49 | 74.97B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
603.30 | 36.08B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.81 | 31.19B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
259.80 | 27.56B | 3.32B | -860.46M | -1.04B | -8.32 |
Cara Therapeutics Inc Stock (CARA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-06-13 | ダウングレード | Canaccord Genuity | Buy → Hold |
| 2024-06-13 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2024-06-13 | ダウングレード | Needham | Buy → Hold |
| 2024-06-13 | ダウングレード | Stifel | Buy → Hold |
| 2023-03-08 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2022-03-08 | アップグレード | JP Morgan | Neutral → Overweight |
| 2021-11-01 | 再開されました | Canaccord Genuity | Buy |
| 2021-08-03 | 開始されました | JP Morgan | Neutral |
| 2020-04-21 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-08-12 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-05-29 | 繰り返されました | Laidlaw | Buy |
| 2019-02-06 | 再開されました | Jefferies | Buy |
| 2019-01-15 | 開始されました | BofA/Merrill | Neutral |
| 2018-09-21 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-09-13 | 開始されました | Jefferies | Buy |
| 2018-08-08 | 繰り返されました | Stifel | Buy |
| 2018-06-28 | 繰り返されました | H.C. Wainwright | Buy |
| 2018-03-12 | 再開されました | H.C. Wainwright | Buy |
| 2018-02-12 | アップグレード | Janney | Neutral → Buy |
| 2018-01-19 | 開始されました | Seaport Global Securities | Buy |
| 2017-06-30 | ダウングレード | Janney | Buy → Neutral |
| 2017-06-30 | 繰り返されました | Laidlaw | Buy |
| 2017-06-30 | 繰り返されました | Stifel | Buy |
| 2017-03-28 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-03-28 | 繰り返されました | Laidlaw | Buy |
| 2017-03-10 | 繰り返されました | Laidlaw | Buy |
| 2016-10-13 | 開始されました | H.C. Wainwright | Buy |
| 2016-08-08 | 繰り返されました | Needham | Buy |
すべてを表示
Cara Therapeutics Inc (CARA) 最新ニュース
Cara shares jump 32% following reverse stock split - MSN
Cara Therapeutics executive Scott Terrillion sells $775 in stock By Investing.com - Investing.com Canada
When the Price of (CARA) Talks, People Listen - Stock Traders Daily
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BLUE, VOXX, CARA, CYTH on Behalf of Shareholders - The Malaysian Reserve
CARA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cara Therapeutics, Inc.CARA - Business Wire
Tharimmune (NASDAQ:THAR) and Cara Therapeutics (NASDAQ:CARA) Head-To-Head Review - Armenian Reporter
Cara Therapeutics, Inc. (NASDAQ:CARA) Given Average Rating of “Hold” by Brokerages - Defense World
Comparing Cara Therapeutics (NASDAQ:CARA) & Tharimmune (NASDAQ:THAR) - Defense World
Cara Therapeutics CEO Christopher Posner sells $1,755 in stock By Investing.com - Investing.com South Africa
Cara Therapeutics CEO Posner sells shares worth $1,755 - MSN
Cara Therapeutics CEO Christopher Posner sells $1,755 in stock - MSN
Cara Therapeutics CEO Posner sells shares worth $1,755 By Investing.com - Investing.com Nigeria
Cara Therapeutics 8-K SEC Filing Reveals Merger Plans with Tvardi Therapeutics - Defense World
Cara Therapeutics, Inc. (NASDAQ:CARA) Receives Average Rating of “Hold” from Brokerages - Defense World
Cara Therapeutics Announces Merger with Tvardi Therapeutics - TipRanks
Cara Therapeutics regains Nasdaq compliance - Investing.com India
Cara Therapeutics Begin Trading On Reverse Split-Adjusted Basis - Nasdaq
Midday Market Movers: Biggest Stock Declines of the Day – Market - HPBL
Cara Therapeutics Shares Surge 20% After 1-for-20 Reverse Stock Split – Market - HPBL
Cara Therapeutics (NASDAQ:CARA) Coverage Initiated at StockNews.com - Defense World
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates ML, PWOD, NURO, CARA on Behalf of Shareholders - The Malaysian Reserve
Cara Therapeutics Files Certificate of Amendment for Reverse Stock Split and Shares Reduction - Defense World
Cara Therapeutics, Inc. Announces Appointment of Joseph Stauffer as Chief Medical Officer - Marketscreener.com
Cara Therapeutics, Inc. Announces Outcome from Dose- Finding Part A of the KIND 1 Study Evaluating Oral Difelikefalin for Mod Moderate-To-Severe Pruritus in Patients with Atopic Dermatitis - Marketscreener.com
Cara Therapeutics discontinues neurological condition study as drug fails - Marketscreener.com
Cara: Q2 Earnings Snapshot - Marketscreener.com
Cara Therapeutics stock hits 52-week high at $4.26 By Investing.com - Investing.com Nigeria
Cara Therapeutics Shares Rise 20% Following Reverse Stock Split - MarketWatch
Stock market news: Coeptis Therapeutics Holdings -96.03%, OptiNose -93.07% among biggest losers during mid day trading - Business Upturn
Stock market news: Coeptis Therapeutics Holdings declined by 96.03% whereas Baird Medical Investment Holdings +496.89% during mid day trading - Business Upturn
Stock market today: Coeptis Therapeutics Holdings -95.79%, OptiNose -93.64% among biggest losers in early trading - Business Upturn
Stock market today: Coeptis Therapeutics Holdings plunged by 95.98% whereas Baird Medical Investment Holdings gained over 201.90% in early trading - Business Upturn
Cara Therapeutics stock hits 52-week high at $4.26 - Investing.com India
Cara to cut 50% of workforce, end CKD program to extend cash runway to 2026 - MSN
Cara Therapeutics announces effective date for 1-for-12 reverse stock split - Hartford Business Journal
Cara Therapeutics announces 1-for-12 reverse stock split to regain Nasdaq compliance - MSN
Cara Therapeutics to Implement 1-for-12 Reverse Stock Split - Marketscreener.com
Cara Therapeutics enacts reverse stock split - Investing.com
Cara Therapeutics Inc (CARA) 財務データ
収益
当期純利益
現金流量
EPS
Cara Therapeutics Inc (CARA) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Terrillion Scott | SEC'Y; CHIEF COMPLIANCE & G.C. |
Feb 28 '25 |
Sale |
4.76 |
163 |
776 |
7,190 |
| Posner Christopher | PRESIDENT AND CEO |
Feb 04 '25 |
Sale |
4.72 |
372 |
1,756 |
13,692 |
| Posner Christopher | PRESIDENT AND CEO |
Nov 04 '24 |
Sale |
0.29 |
3,668 |
1,064 |
168,768 |
| Posner Christopher | PRESIDENT AND CEO |
Aug 01 '24 |
Sale |
0.35 |
4,149 |
1,452 |
172,436 |
| Posner Christopher | PRESIDENT AND CEO |
May 02 '24 |
Sale |
0.75 |
3,936 |
2,952 |
176,585 |
| Goncalves Joana | CHIEF MEDICAL OFFICER |
Apr 05 '24 |
Sale |
0.83 |
2,753 |
2,285 |
53,365 |
| Terrillion Scott | SEC'Y; CHIEF COMPLIANCE & G.C. |
Apr 05 '24 |
Sale |
0.83 |
2,753 |
2,285 |
88,247 |
1.28%
0.80%
大文字化:
|
ボリューム (24 時間):